PMID- 32595733
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240328
IS  - 1741-427X (Print)
IS  - 1741-4288 (Electronic)
IS  - 1741-427X (Linking)
VI  - 2020
DP  - 2020
TI  - Chrysophanol Regulates Cell Death, Metastasis, and Reactive Oxygen Species 
      Production in Oral Cancer Cell Lines.
PG  - 5867064
LID - 10.1155/2020/5867064 [doi]
LID - 5867064
AB  - BACKGROUND: Oral cancer belongs to the class of head and neck cancers and can be 
      life threatening if not diagnosed and treated early. Activation of cell death via 
      apoptosis or reactive oxygen species (ROS) accumulation and inhibition of cell 
      cycle progression, migration, and epithelial-to-mesenchymal transition (EMT) may 
      be a good strategy to arrest the development of oral cancer. In this study, we 
      analyzed the possible action of chrysophanol isolated from the rhizomes of Rheum 
      palmatum on the oral cancer cell lines FaDu (human pharynx squamous cell 
      carcinoma) and SAS (human tongue squamous carcinoma) by investigating whether 
      chrysophanol could influence cell death. METHOD: Cell viability was measured by 
      using the MTT assay. For the detection of apoptosis, terminal deoxynucleotidyl 
      transferase dUTP nick-end labeling (TUNEL) staining and subG1 population analysis 
      were used. We also examined cell cycle progression and ROS levels by flow 
      cytometry. Additionally, the expression of p53, p21, procaspase 3, cyclin D1, 
      CDK4, cdc2, CDK2, E-cadherin, vimentin, and PCNA was evaluated by western 
      blotting. CONCLUSION: Chrysophanol has an anticancer effect on FaDu and SAS cell 
      lines. There is an increase in subG1 accumulation, ROS production, and cell cycle 
      G1 arrest after treatment with chrysophanol. On the other hand, chrysophanol 
      inhibited cell migration/metastasis and EMT. We proposed that chrysophanol may be 
      a good candidate compound on oral cancer treatment in the further.
CI  - Copyright (c) 2020 Po-Chih Hsu et al.
FAU - Hsu, Po-Chih
AU  - Hsu PC
AUID- ORCID: 0000-0003-2598-1776
AD  - Graduate Institute of Medical Sciences, National Defense Medical Center, Taipei, 
      Taiwan.
AD  - Department of Dentistry, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical 
      Foundation, New Taipei City, Taiwan.
FAU - Cheng, Ching-Feng
AU  - Cheng CF
AD  - Department of Pediatrics, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical 
      Foundation, New Taipei City, Taiwan.
AD  - Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan.
AD  - Department of Pediatrics, Tzu Chi University, Hualien, Taiwan.
FAU - Hsieh, Po-Chun
AU  - Hsieh PC
AUID- ORCID: 0000-0002-0416-8797
AD  - Department of Chinese Medicine, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical 
      Foundation, New Taipei City, Taiwan.
FAU - Chen, Yi-Hsuan
AU  - Chen YH
AUID- ORCID: 0000-0002-6455-8551
AD  - Department of Research, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical 
      Foundation, New Taipei City, Taiwan.
FAU - Kuo, Chan-Yen
AU  - Kuo CY
AUID- ORCID: 0000-0002-5702-5730
AD  - Department of Research, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical 
      Foundation, New Taipei City, Taiwan.
FAU - Sytwu, Huey-Kang
AU  - Sytwu HK
AUID- ORCID: 0000-0001-8937-0769
AD  - National Institute of Infectious Diseases and Vaccinology, National Health 
      Research Institutes, Zhunan, Miaoli County, Taiwan, China.
AD  - Department of Microbiology and Immunology, National Defense Medical Center, 
      Taipei, Taiwan, China.
LA  - eng
PT  - Journal Article
DEP - 20200526
PL  - United States
TA  - Evid Based Complement Alternat Med
JT  - Evidence-based complementary and alternative medicine : eCAM
JID - 101215021
PMC - PMC7271060
COIS- The authors declare no conflicts of interest.
EDAT- 2020/07/01 06:00
MHDA- 2020/07/01 06:01
PMCR- 2020/05/26
CRDT- 2020/06/30 06:00
PHST- 2019/12/19 00:00 [received]
PHST- 2020/03/20 00:00 [revised]
PHST- 2020/04/20 00:00 [accepted]
PHST- 2020/06/30 06:00 [entrez]
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2020/07/01 06:01 [medline]
PHST- 2020/05/26 00:00 [pmc-release]
AID - 10.1155/2020/5867064 [doi]
PST - epublish
SO  - Evid Based Complement Alternat Med. 2020 May 26;2020:5867064. doi: 
      10.1155/2020/5867064. eCollection 2020.